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(Macro)Autophagy is a process that delivers cellular con-
stituents for lysosomal degradation. Autophagy is important
in cancer with both pro- and anti-tumourigenic roles being
reported [1]. Melanoma is a cancer originating from mela-
nocytes and frequently develops in UV-exposed skin [2]. To
examine autophagy’s role in melanoma we utilized a mouse
model containing an allele of the BrafV600E mutation (the
signature molecular driver of human melanoma [3]) pre-
ceded by a Lox-STOP-Lox cassette [4]. These mice were
crossed to animals bearing a floxed allele of Pten, which can
accelerate the disease, and/or animals carrying floxed alleles
of the essential autophagy gene Atg7 [5, 6]. Recombination
of alleles was achieved by topical application of tamoxifen
to activate an inducible Cre-recombinase (Cre-ER) under
control of the Tyrosinase (Tyr) promoter [7]. In BrafV600E
mice wild-type for Pten (Tyr-Cre:ER Pten+/+ BrafV600E/+),
deletion of Atg7 (Tyr-Cre:ER Pten+/+ BrafV600E/+ Atg7−/−)
significantly accelerated melanoma onset (Fig. 1, Table S1).
In contrast, in mice hemizygous for Pten (Tyr-Cre:ER
Pten+/− BrafV600E/+) melanoma onset was accelerated, but
no difference was observed upon Atg7 deletion (Fig. 1,
Table S2). Immunohistochemistry for ATG7, LC3 and
p62/SQSTM1 established the presence/absence of autophagy
and positivity for S100 confirmed melanocytic origin of
tumour cells (Fig. S1). Our findings show autophagy is
dispensable for melanoma growth and might support a bar-
rier function for melanoma development that is compromised
in animals hemizygous for Pten that eventually lose the
remaining wild-type allele during disease progression [5].
A potential explanation for our findings might be the
connection between autophagy and senescence. Senescence
is a terminal cell cycle arrest that serves as a barrier to block
malignant progression [8]. Nevi can progress to melanoma if
the senescent barrier is breached and downregulation of
ATG5 prevents oncogene-induced senescence in primary
human melanocytes [9]. As our model develops senescent
nevi before invasive melanoma occurs [4], it is conceivable
that acceleration of melanoma onset upon Atg7 deletion is
due to a senescence defect. This suggests that Atg7-deletion
should not have the same impact in the context of Pten-
deficiency, as PI3K pathway activation via Pten deletion is
known to abrogate oncogene-induced senescence and con-
tributes to melanoma development [10]. The pro-senescence
features of autophagy would then be superfluous and
autophagy-deletion would not impact on melanoma onset.
Our results are in contrast to work from Xie and col-
leagues who found that Atg7-deletion prevents tumour
formation in the context of Pten deletion [11]. A possible
explanation for this discrepancy is the different models
used. Xie et al. used mice that upon BrafV600E activation
developed pigmented skin lesions, but failed to progress to
invasive melanoma unless combined with loss of PTEN,
which would impair senescence from the outset of tumour
development [5, 10, 11]. In this case, autophagy loss
impairs disease progression by modulating oxidative stress.
In contrast, we relied on a different model [4] in which
BRAFV600E expression alone is sufficient for melanoma
development once the senescence barrier is breached at a
point during disease progression or, in our case, when
combined with loss of an essential autophagy gene.
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The reason for the different phenotypic effects seen in these
two models of melanoma is unknown. It may be that subtle
differences in the strategies for gene targeting [12, 13], the
use of different Cre lines [7, 14] or differences in the strain
background of the animals used in the different studies
could all contribute to the differences observed. While this
is however speculation, what is clear is that the profound
phenotypic differences observed imply significant genetic
intricacies that lead to different autophagy dependencies
that are affected by Pten status in these two mouse models.
It is natural to question how these findings relate to the
role of autophagy in human melanoma. Like in many can-
cers, autophagy is considered tumour suppressive in the
transition from benign to malignant disease, but conversely
tumour promoting in established melanoma [15, 16]. Our
data support a tumour preventive role in the early stages of
melanoma development, and as mentioned above, a previous
study has shown that ATG5 is down-regulated at this stage
of human melanoma resulting in enhanced proliferation and
bypass of senescence [9]. Another study also showed that
hemizygous loss of ATG5 occurs during melanoma devel-
opment [17], but as loss of one allele of ATG5 would not be
predicted to inhibit autophagy, this raises the question
whether the driver for this loss is an autophagy-independent
effect of ATG5. However, while these caveats are possible,
there is clear evidence that accumulation of the autophagic
substrate p62/SQSTM1 is pro-tumorigenic [18, 19], sug-
gesting that there is pressure to lose or at least temporarily
inactivate autophagy during the progression of this disease.
Methods
Animal experiments
Mouse strains were described previously [4–6] and of C57BL/
6 background. All experiments were carried out in compliance
with UK Home Office regulations (Project license number:
P54E3DD25). Melanocyte specific recombination was
achieved by topical application of 1mg/d tamoxifen for five
consecutive days on the shaven back to activate an inducible
Cre-recombinase under control of the Tyrosinase (Tyr) pro-
motor [7]. Experimental mice were 73+/− 7d old and of
equal gender distribution. Animals were monitored thrice
weekly for tumour formation and sacrificed once end point
criteria were met (melanoma >= 15mm, ulceration, sig-
nificant weight loss, weakness and inactivity). Kaplan–Meier
curves represent time to tumour onset. Censored animals had
to be sacrificed because they reached endpoint criteria or old
age without evidence of melanoma. After euthanasia tissue
was excised and fixed in 10 % buffered formalin for 24–48 h
at room temperature. Fixed tissue was paraffin embedded and
4 µm sections were prepared for hematoxylin and eosin (HE)
staining and immunohistochemistry.
Immunohistochemistry
The following antibodies were used: ATG7 rabbit mono-
clonal (Cell Signaling, 8558), S100 rabbit polyclonal
(Dako, Z031129), LC3 mouse monoclonal (Nanotools,
5F10), and P62 rabbit polyclonal (Enzo Lifesciences, BML-
PW9860). Immunohistochemistry was performed using
heat induced epitope retrieval for ATG7 and LC3 with
Target Retrieval Solution pH9.0 (Agilent/Dako, K800421-
2), for P62 with Target Retrieval Solution pH6.1 (Agilent/
Dako, K800521-2) and for S100 with citric acid at pH6.0.
ATG7 and LC3 were visualized with SuperVision 2 HRP
(mouse/rabbit) (DCS Innovative Diagnostik-Systeme,
PD000POL) and p62 and S100 with HiDef Detection™
HRP Polymer System (Cell Marque, 954D-40).
Statistical analyses
Statistical analyses were carried out using IBM SPSS Sta-
tistics version 21 for Windows. A log-rank test was used to
determine significance in Kaplan-Meier curves.
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Fig. 1 Impact of autophagy deletion on melanoma development.
Kaplan–Meyer curves depicting tumour onset of the indicated geno-
types. A Log-Rank test was used to compare the tumour onset dis-
tribution and p < 0.05 was considered statistically significant.
Censored animals had to be sacrificed because they reached endpoint
criteria or old age without evidence of melanoma.
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